Currently, many targets, such as epidermal growth factor receptor variant III, interleukin (IL)–13Rα2, B7 homolog 3 protein (also known as CD276), CD70, ganglioside GD2, matrix metalloproteinase-2, and natural killer group 2, member D, have been used in preclinical and clinical studies of CAR-T therapy conducted on GBM [14]. The gene discussed is CD276; the disease is glioblastoma.